BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021;131:e152264. [PMID: 34464358 DOI: 10.1172/JCI152264] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 37.0] [Reference Citation Analysis]
Number Citing Articles
1 Strengers P, O'brien SF, Politis C, Mayr W, Seifried E, Spencer BR. White paper on pandemic preparedness in the blood supply. Vox Sanguinis 2022. [DOI: 10.1111/vox.13378] [Reference Citation Analysis]
2 Kimber C, Lamikanra AA, Geneen LJ, Sandercock J, Dorée C, Valk SJ, Estcourt LJ. A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfusion Medicine 2022. [DOI: 10.1111/tme.12942] [Reference Citation Analysis]
3 Kiss-dala N, Szabo BG, Lakatos B, Reti M, Szlavik J, Valyi-nagy I. Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. GeroScience 2022. [DOI: 10.1007/s11357-022-00683-4] [Reference Citation Analysis]
4 Körper S, Schrezenmeier EV, Rincon-arevalo H, Grüner B, Zickler D, Weiss M, Wiesmann T, Zacharowski K, Kalbhenn J, Bentz M, Dollinger MM, Paul G, Lepper PM, Ernst L, Wulf H, Zinn S, Appl T, Jahrsdörfer B, Rojewski M, Lotfi R, Dörner T, Jungwirth B, Seifried E, Fürst D, Schrezenmeier H. Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19. Front Immunol 2022;13:1008438. [DOI: 10.3389/fimmu.2022.1008438] [Reference Citation Analysis]
5 White H, Mcdonald SJ, Barber B, Davis J, Burr L, Nair P, Mukherjee S, Tendal B, Elliott J, Mcgloughlin S, Turner T. Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce. Medical Journal of Australia 2022;217:368-378. [DOI: 10.5694/mja2.51718] [Reference Citation Analysis]
6 Villanueva C, Neyra I, Sagastegui A, Chunga A, Oyanguren M, Guillermo-roman M, Soto-ordoñez S, Maguiña JL, Hurtado-roca Y, Soto-becerra P, Araujo-castillo RV. Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial.. [DOI: 10.1101/2022.09.21.22280195] [Reference Citation Analysis]
7 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Joyner MJ, Carter RE, Fairweather D, Wright RS. Convalescent plasma and COVID ‐19: Time for a second—second look? Transfusion Medicine. [DOI: 10.1111/tme.12915] [Reference Citation Analysis]
9 Battaglini D, Cruz F, Robba C, Pelosi P, Rocco PRM. Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opin Investig Drugs 2022. [PMID: 36047644 DOI: 10.1080/13543784.2022.2120801] [Reference Citation Analysis]
10 Zhou CK, Bennett MM, Villa CH, Hammonds KP, Lu Y, Ettlinger J, Priest EL, Gottlieb RL, Davis S, Mays E, Clarke TC, Shoaibi A, Wong H, Anderson SA, Kelly RJ. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19. PLoS ONE 2022;17:e0273223. [DOI: 10.1371/journal.pone.0273223] [Reference Citation Analysis]
11 Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, Allen ES, Bloch EM, Beaudoin G, Casadevall A, Devine DV, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Grossman BJ, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Tobian AAR. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med 2022. [PMID: 35969859 DOI: 10.7326/M22-1079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lacombe K, Hueso T, Porcher R, Mekinian A, Chiarabini T, Georgin-lavialle S, Ader F, Saison J, Blondel GM, De Castro N, Bonnet F, Cazanave C, François A, Morel P, Hermine O, Pourcher V, Michel M, Lescure X, Soussi N, Brun P, Pommeret F, Sellier P, Rousset S, Piroth L, Michot J, Baron G, De Lamballerie X, Mariette X, Tharaux P, Resche-rigon M, Ravaud P, Simon T, Tiberghien P. Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial.. [DOI: 10.1101/2022.08.09.22278329] [Reference Citation Analysis]
13 Qian Z, Zhang Z, Ma H, Shao S, Kang H, Tong Z. The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Front Immunol 2022;13:964398. [DOI: 10.3389/fimmu.2022.964398] [Reference Citation Analysis]
14 Rahimi-levene N, Shapira J, Tzur I, Shiloah E, Peer V, Levin E, Izak M, Shinar E, Ziv-baran T, Weinberger M, Zimhony O, Chen J, Maor Y. Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy. PLoS ONE 2022;17:e0271036. [DOI: 10.1371/journal.pone.0271036] [Reference Citation Analysis]
15 Metcalf RA, Cohn CS, Allen ES, Bakhtary S, Gniadek T, Gupta G, Harm S, Haspel R, Hess A, Jacobson J, Lokhandwala PM, Murphy C, Poston J, Prochaska MT, Raval JS, Saifee NH, Salazar E, Shan H, Zantek N, Pagano MB. Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion 2022. [PMID: 35713186 DOI: 10.1111/trf.16944] [Reference Citation Analysis]
16 Belov A, Huang Y, Villa CH, Whitaker BI, Forshee R, Anderson SA, Eder A, Verdun N, Joyner MJ, Wright SR, Carter RE, Hung DT, Homer M, Hoffman C, Lauer M, Marks P; Broad Institute COVID-19 Antibody Team. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 2022;97:770-9. [PMID: 35303377 DOI: 10.1002/ajh.26531] [Reference Citation Analysis]
17 Song ATW, Rocha V, Mendrone-Júnior A, Calado RT, De Santis GC, Benites BD, Costa-Lima C, Vargas T, Marques LS, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Avelino-Silva VI, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Reg Health Am 2022;10:100216. [PMID: 35308034 DOI: 10.1016/j.lana.2022.100216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang S, Tong Y, Chen L, Yu W. Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19. Mol Biomed 2022;3:15. [PMID: 35593963 DOI: 10.1186/s43556-022-00077-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study.. [DOI: 10.1101/2022.04.29.22274387] [Reference Citation Analysis]
20 Bein G. Die Dosis macht das Gift (Dosis-Wirkungs-Beziehung). Transfusionsmedizin 2022;12:73-74. [DOI: 10.1055/a-1623-8779] [Reference Citation Analysis]
21 Gray PE, Bartlett AW, Tangye SG. Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals. Clin Transl Immunology 2022;11:e1365. [PMID: 35444807 DOI: 10.1002/cti2.1365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bajpai M, Maheshwari A, Dogra V, Kumar S, Gupta E, Kale P, Saluja V, Thomas SS, Trehanpati N, Bihari C, Agarwal R, Bharti P, Shankar P, Hussain J, Chhabra K, Gupta A, Narayanan A, Agarwal S, Jain S, Bhardwaj A, Kumar G, Yadav BK, Sarin SK. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open 2022;12:e055189. [PMID: 35387813 DOI: 10.1136/bmjopen-2021-055189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
23 Alfano G, Morisi N, Frisina M, Ferrari A, Fontana F, Tonelli R, Franceschini E, Meschiari M, Donati G, Guaraldi G. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. Infez Med 2022;30:11-21. [PMID: 35350263 DOI: 10.53854/liim-3001-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, Kurolt IC, Mačak Šafranko Ž, Mušlin T, Rnjak D, Jakšić O, Sorić E, Džepina G, Đaković Rode O, Kujavec Šljivac K, Vuk T, Jukić I, Markotić A, Halassy B. Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible? Front Immunol 2022;13:816159. [PMID: 35273599 DOI: 10.3389/fimmu.2022.816159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Franchini M, Glingani C, Donno GD, Lucchini G, Beccaria M, Amato M, Castelli GP, Bianciardi L, Pagani M, Ghirardini M, Puma G, Presciuttini B, Costantino MT, Frigato M, Crosato V, Tiecco G, Mulè A, Papalia DA, Inglese F, Spreafico F, Garuti M, Pecoriello A, Cervi G, Greco G, Galavotti V, Santini T, Berselli A, Montalto C, Bertoletti R, Bellometti SA, Capuzzo E, Benazzi D, Grisolia G, Pajola F, Stradoni R, Zani M, Verzola A, Codeluppi V, Vesentini S, Bellocchio E, Candini M, Ambrosi G, Carandina F, Scarduelli C, Reggiani A, Casari S; on behalf of Convalescent Plasma Study Group. Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience. Life 2022;12:420. [DOI: 10.3390/life12030420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 González SE, Regairaz L, Salazar MR, Ferrando NS, González Martínez VV, Carrera Ramos PM, Pesci SA, Vidal JM, Kreplak N, Estenssoro E. Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. J Investig Med. [DOI: 10.1136/jim-2021-002158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yang P, Wang J, Zheng R, Tan R, Li X, Liu X, Li Y, Yuan Z, Wang Y, Chen Q, Yu J. Convalescent plasma transfusion therapy in severe and critical COVID-19 patients: A Systematic Review and Meta-Analysis. Heart & Lung 2022. [DOI: 10.1016/j.hrtlng.2022.01.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arcanjo GGA, Oliveira ÉAF, Tonacio AC, Langhi DM Jr, Bordin JO, Gilio RN, Palma LC, Santos EV, Haddad SK, Prado BPA Jr, Pontelli MC, Gomes R, Miranda CH, Martins MA, Covas DT, Arruda E, Fonseca BAL, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis 2022;28. [PMID: 35081022 DOI: 10.3201/eid2803.212299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
29 Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 De Silvestro G, Marson P, La Raja M, Cattelan AM, Guarnieri G, Monticelli J, Tiberio I, Vianello A, Gandini G, Gessoni G, Fiorin F, Sardella C, Astolfi L, Saia M; Veneto Hospitals. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Eur J Intern Med 2021:S0953-6205(21)00433-7. [PMID: 34980505 DOI: 10.1016/j.ejim.2021.12.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
31 Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group . Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med 2021. [PMID: 34901997 DOI: 10.1001/jamainternmed.2021.6850] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 17.0] [Reference Citation Analysis]
32 Estcourt LJ. Passive immune therapies: another tool against COVID-19. Hematology Am Soc Hematol Educ Program 2021;2021:628-41. [PMID: 34889410 DOI: 10.1182/hematology.2021000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Focosi D, Franchini M, Pirofski LA, Maggi F, Casadevall A. Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics? Rev Med Virol 2021;:e2314. [PMID: 34861088 DOI: 10.1002/rmv.2314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Menichetti F, Falcone M, Tiseo G. Management of COVID patients with convalescent plasma: Do we have the final word? Eur J Intern Med 2021:S0953-6205(21)00368-X. [PMID: 34895816 DOI: 10.1016/j.ejim.2021.10.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Körper S, Appl T, Jahrsdörfer B, Lotfi R, Rojewski M, Wuchter P, Tonn T, Bakchoul T, Karatas M, Schmidt M, Klüter H, Seifried E, Schrezenmeier H. Randomisierte Studien zum Einsatz von Rekonvaleszentenplasma bei COVID-19: eine Standortbestimmung. Transfusionsmedizin 2021;11:223-240. [DOI: 10.1055/a-1521-7884] [Reference Citation Analysis]
36 Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, Falcone M; TSUNAMI Study group. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e2136246. [PMID: 34842924 DOI: 10.1001/jamanetworkopen.2021.36246] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 27.0] [Reference Citation Analysis]
37 Rincon-Arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, Stefanski L, Lino AC, Körper S, Eckardt KU, Schrezenmeier H, Dörner T, Schrezenmeier EV. Altered increase in STAT1 expression and phosphorylation in severe COVID-19. Eur J Immunol 2021. [PMID: 34676541 DOI: 10.1002/eji.202149575] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
38 Ling RR, Sim JJL, Tan FL, Tai BC, Syn N, Mucheli SS, Fan BE, Mitra S, Ramanathan K. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Transfus Med Rev 2021:S0887-7963(21)00056-0. [PMID: 34782209 DOI: 10.1016/j.tmrv.2021.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]